市場調查報告書

Filgotinib:新的醫藥品的考察與至2030年的市場預測

Filgotinib - Emerging Drug Insight and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 968229
出版日期 內容資訊 英文 50 Pages
商品交期: 最快1-2個工作天內
價格
Filgotinib:新的醫藥品的考察與至2030年的市場預測 Filgotinib - Emerging Drug Insight and Market Forecast - 2030
出版日期: 2020年10月31日內容資訊: 英文 50 Pages
簡介

以Jyseleca品牌名所販售Filgotinib,是類風濕性關節炎的治療使用的藥,由GalapagosNV開發。最常見的副作用,有噁心,上呼吸道感染,泌尿道感染,暈眩等。 2020年8月,Gilead Sciences宣佈,美國食品藥物管理局(FDA),已針對中度到重度的活動性類風濕性關節炎(RA)臨床實驗藥的Filgotinib發出對於新藥認證申請(NDA)的非核准通知(CRL)。

本報告提供美國,德國,法國,義大利,西班牙,英國,日本主要7個國家類風濕性關節炎臨床實驗藥Filgotinib的調查,提供醫藥品概要,市場評估,SWOT分析,分析師的見解,競爭情形,其他新的治療藥等資訊。

目錄

第1章 醫藥品概要

  • 產品詳細內容
  • 作用機制
  • 投藥和管理
  • 研究開發活動
    • 臨床開發
    • 安全性和有效性
  • 其他開發活動

第2章 市場評估

  • 主要7個國家的市場分析
  • 美國市場
  • 德國市場
  • 法國市場
  • 義大利市場
  • 西班牙市場
  • 英國市場
  • 日本市場

第3章 SWOT分析

第4章 分析師的見解

第5章 競爭產品

第6章 其他新的治療方法

第7章 附錄

第8章 報告的購買選擇

目錄
Product Code: DIDM0084

"Filgotinib - Emerging Drug Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Rheumatoid Arthritis in 7 Major Markets. A detailed picture of the FILGOTINIB in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Overview:

Filgotinib, sold under the brand name Jyseleca, is a medication used for the treatment of rheumatoid arthritis. It was developed by the Belgian-Dutch biotech company Galapagos NV. The most common side effects include nausea, upper respiratory tract infection, urinary tract infection and dizziness. In August 2020, Gilead Sciences announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the New Drug Application (NDA) for filgotinib, an investigational treatment for moderately to severely active rheumatoid arthritis (RA).

Scope of the report:

The report provides insights into:

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug research and development activity details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around Filgotinib.
  • The report contains forecasted sales for Filgotinib till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase III) for Rheumatoid Arthritis.
  • The report also features the SWOT analysis with analyst insights and key findings of Filgotinib.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Filgotinib Analytical Perspective by DelveInsight

  • In-depth Filgotinib Market Assessment

This report provides a detailed market assessment of Filgotinib in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

  • Filgotinib Clinical Assessment

The report provides the clinical trials information of Filgotinib covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights:

  • In the coming years, the market scenario for Rheumatoid Arthritis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Filgotinib dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other emerging products for Rheumatoid Arthritis are giving market competition to Filgotinib and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of Filgotinib.
  • Our in-depth analysis of the forecasted sales data of Filgotinib from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Filgotinib.

Key Questions:

  • Which company is developing Filgotinib along with the phase of the clinical study?
  • What is the technology utilized in the development of Filgotinib?
  • What is the product type, route of administration and mechanism of action of Filgotinib?
  • What is the clinical trial status of the study and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Filgotinib development?
  • What are the key designations that have been granted to Filgotinib?
  • What is the forecasted market scenario of Filgotinib?
  • What is the history of Filgotinib and what is its future?
  • What is the forecasted sales of Filgotinib in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available and how these are giving competition to Filgotinib?
  • Which are the late-stage emerging therapies under development for the treatment of the PPD?

Table of Contents

1. Drug Overview

  • 1.1. Product Detail
  • 1.2. Mechanism of Action
  • 1.3. Dosage and Administration
  • 1.4. Research and development activity
    • 1.4.1. Clinical Development
    • 1.4.2. Safety and Efficacy
  • 1.5. Other Development Activities

2. Market Assesment

  • 2.1. 7MM Market Analysis
  • 2.2. The United States Market
  • 2.3. Germany Market
  • 2.4. France Market
  • 2.5. Italy Market
  • 2.6. Spain Market
  • 2.7. United Kingdom Market
  • 2.8. Japan Market

3. SWOT Analysis

4. Analyst Views

5. Market Competitors

6. Other Emerging Therapies

7. Appendix

8. Report Purchase Options

List of Tables

  • Table 1 FILGOTINIB, Description
  • Table 2 FILGOTINIB, Clinical Trial Description
  • Table 3 FILGOTINIB, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Table 4 Market Competitors
  • Table 5 Other Emerging Therapies

List of Figures

  • Figure 1 The Development Timeline of FILGOTINIB
  • Figure 2 Patent Details, FILGOTINIB
  • Figure 3 FILGOTINIB, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Figure 4 FILGOTINIB, US Market Size from 2020 to 2030 (in Millions USD)
  • Figure 5 FILGOTINIB, EU5 Market Size from 2020 to 2030 (in Millions USD)
  • Figure 6 FILGOTINIB, Japan Market Size from 2020 to 2030 (in Millions USD)